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The present study investigated posttranslational reactions in the salivary glands of patients with Sjögren’s syndrome. We analysed
the biopsies of primary Sjögren’s patients using immunohistochemistry and a tag-purified anticyclic citrullinated protein (CCP)
antibody to detect citrullinated peptides, and the presence of peptidylarginine deiminase 2 (PAD2) was assessed simultaneously.
The present work demonstrated the weak presence of the PAD2 enzyme in some normal salivary glands, although PAD2 expression
was increased considerably in Sjögren’s patients. The presence of citrullinated proteins was also detected in the salivary tissues of
Sjögren’s patients, which strongly supports the in situ posttranslational modification of proteins in this setting. Furthermore, the
mutual expression of CCP and PAD2 suggests that this posttranslational modification is enzyme dependent. In conclusion, patients
with Sjögren’s syndrome expressed the catalytic machinery to produce posttranslational reactions that may result in autoantigen
triggering.
1. Introduction
Sjögren’s syndrome is an autoimmune epithelitis that pri-
marily affects the salivary and lachrymal glands and results
clinically in Sicca syndrome, which is characterised by xeros-
tomia, xerophthalmia, and keratoconjunctivitis [1].
Citrulline is an 𝛼-amino acid that can be isolated from
watermelon [2]. In addition, it is an intermediate compound
of the urea cycle and is synthesised in the liver by the
conversion of ornithine to arginine during urea formation
[3]. Citrulline exists in two forms: free citrulline, which is a
product of the NOS enzyme family, and citrulline that results
from the posttranslational modification of certain proteins
at arginine residues, which is catalysed by peptidylarginine
deiminases (PADs). This family of enzymes deiminates pro-
teins at arginine residues to yield citrulline residues, and in
this manner, protein citrullination is NOS independent [4].
We previously demonstrated inflammatory citrullination
in the salivary glands of Sjögren’s syndrome patients that was
partially dependent on iNOS. This enzyme is overexpressed
in inflammatory cells and infiltrates of the acini and salivary
epithelia, and the in situ NO overdrive may contribute
to glandular damage [5]. TNF and other proinflammatory
cytokines are frequently observed in the glandular tissues of
these patients, and these factors may trigger the production
of iNOS [6]. Although protein citrullination is an important
event in rheumatoid arthritis pathogenesis [7, 8], this process
may also occur in Sjögren’s syndrome. Approximately 7.5%
of primary Sjögren’s syndrome patients are positive for
anticyclic citrullinated protein (anti-CCP) antibodies [9], and
the presence of this marker in Sjögren’s syndrome may be
associated with nonerosive arthritis [10]. Protein citrullina-
tion has been shown to be an important pathophysiological
mechanism in rheumatoid arthritis, and this process has
also been reported in other autoimmune diseases such as
antibody-associated neurodegenerative diseases [11]. There-
fore, we investigated protein citrullination at the glandular






































Figure 1: (a) Chromatogram shows the purification of anti-CCP
conjugated antibody that was further fractionated using gel filtration
chromatography, which produced three fractions. The first pool
(tubes 9–11) contained theHRP-anti-CCP conjugates (green) second
pool (tubes 12–14) (pink). Pool 3 (tubes 18–20) contained the
nonconjugated peroxidase fraction (blue). (b) ELISA graph of
different fractions obtained by gel filtration. Pool 1 was very reactive
for CCP, with an optical density that was threefold higher than the
original serum titre. Pool 2 activity was weaker, and pool 3 was
negative. (OD: optical density).
2. Material and Methods
2.1. Tissues. Minor salivary gland biopsies from 24 patients
with primary Sjögren’s syndrome were studied. The patients
fulfilled the revised version of the European criteria pro-
posed by the American-European Consensus [12].This study
included 17 women and seven men with a mean age of 47
years (range, 37–57 years). All of the patients and controls
were informed of the biopsy, and written authorisation was
obtained. An equal number of biopsies were obtained during
oral surgery for other purposes from individuals without
Sjögren’s syndrome,whowere included as controls.The ethics
committee of our institution authorised and monitored the
protocol, which conformed to the requirements of the World
Medical Association’s Declaration of Helsinki.The specimens
were fixed in formaldehyde, embedded in paraffin, sectioned
at a 4𝜇mthickness, and stainedwith haematoxylin and eosin.
Two pathologists microscopically evaluated the biopsies,
which were classified according to the revised multilevel
assessment of a cumulative focus score [13]. Unstained tissue
sections were used for immunohistochemistry.
2.2. Anti-CCP Antibodies. Enzyme immunoassays detected
antibodies against citrullinated synthetic peptides from
vimentin and filaggrin in sera from patients and controls.
Serum from patients with rheumatoid arthritis was used as
a positive control. The assays were performed according to
the manufacturer’s instructions (Euroimmun AG, Luebeck
Germany). First, the serum samples were diluted 1 : 100 in
dilution buffer. Second, the sera dilutions were incubated for
60minutes at room temperature in wells of polystyrene plates
coated with synthetic cyclic citrullinated peptides (CCPs),
which contained arginine-modified residues. The citrulli-
nated synthetic peptides included filaggrin, EBVnuclear anti-
gen, and IgG sequences, and the CCPs included recombinant
rat filaggrin or mutated human vimentin [14]. Third, the
plates were washed with washing buffer. Fourth, the bound
antibodies were tagged with the secondary antibody (conju-
gated POD-rabbit polyclonal anti-human IgG) during a 30-
minute incubation. Fifth, the colour reaction was developed
during a 30-minute incubation with the colour developer
pNPP (p-nitrophenyl phosphate, disodium salt). Sixth, the
reaction was stopped, and the microplates were evaluated
using an ELISA reader at 450 nm. Lastly, five calibrators
were used to construct the curve analysis, and the results are
expressed in units. All assays were performed in triplicate.
2.3. Purification of Affinity-Bound CCP Peptides. A rheuma-
toid arthritis patient who was positive for anti-CCP antibod-
ies (filaggrin or mutated human vimentin) was submitted
to ELISA, as described previously [15]. Specific anti-CCP
bound antibodies were eluted from the polystyrene CCP-
coated plates after a 2-hour incubation using 0.2M glycine-
HCl, pH 2.8, and the eluted antibodies were neutralised with
1M Tris, pH 9.5.The recovered antibodies were concentrated
in a Centricon centrifugal device with a 30 kDa molecular
weight cut-off (Millipore).
2.4. Antibodies Labelling with Peroxidase. Protein concentra-
tions of affinity-purified antibodies were measured using the
Bradford method [16], and the high-affinity-purified anti-
CCP antibodies were labelled with horseradish peroxidase
(HRP) (Sigma, St. Louis, MO) using themethod described by
Avrameas [17] with modifications. Briefly, the molar ratio of
high-affinity-purified antibodies to peroxidase was 1 : 10. The
enzyme was preactivated with glutaraldehyde and incubated
at 37∘C for 30 minutes. The coupling reaction was induced
during an 18-hour incubation at room temperature in a
sodium carbonate buffer, pH 9.5. The Anti-CCP/HRP was
extensively dialysed against distilled H
2
O using a membrane
with a pore size of 40 kDa. The anti-CCP/HRP conjugate
was fractionated in a minicolumn packed with Sephadex G-
200, which had been equilibrated with PBS, and an elution
volume of 120 𝜇L per/fraction was collected in 25 tubes. The
protein concentration was recorded in the different fractions,
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Figure 2: Immunohistochemistry ofminor salivary glands.The superior panel corresponds to normal controls, and the inferior panel belongs
to one representative biopsy of a Sjögren patient. (A) and (E). Incubatedwith PBS. (B) and (F). Treatedwith anti-CCP. (C) and (G). Anti-PAD2.
(D) and (H). Anticitrulline. Observe the immunoreagents positivity at ducts and acini in (F), (G), and (H).
and three pools were created according to the chromatogram.
Direct ELISA assays determined the reactivity to CCP of each
pool, and each pool was concentrated to obtain 33% of the
final volume using a Centricon device.The affinity anti-CCP-
purified antibodies were used to trace CCP antigens in the
salivary glands using immunohistochemistry.
2.5. Immunohistochemistry. Immunohistochemistry was
performed to detect posttranslationally modified proteins
in 4𝜇m-thick sections of fixed minor salivary glands on
microscope slides. The specimens were deparaffinised,
permeabilised with 0.01% Triton X-100/phosphate-buffered
saline (PBS), and washed three times with PBS. Endogenous





methanol. The tissues were incubated with purified human
IgG precipitated from normal human sera with ammonium
sulphate to neutralise the presence of possible rheumatoid
factor activity in salivary glands, and the precipitates were
dialysed against distilled water using Slide-A-Lyzer Dialysis
Cassettes (10 K MWCO Thermo Fisher Scientific Inc.,
Rockford, IL). IgG was purified using HiTrap protein G HP
columns.The tissues were washed and incubated for 12 hours
with an affinity-purified anti-CCP antibody (diluted 1 : 50) in






MO) after washing, and the reaction was stopped with
0.5M sulphuric acid. The slides were examined under a
light microscope. All assays were performed in triplicate and
evaluated in a blinded manner. In addition, an anti-citrulline
antibody (cat. 231246, Calbiochem, Darmstadt, Germany;
1 : 100 dilution in 10% foetal bovine serum (FBS)-PBS) and
an anti-PAD 2 antibody (PA5-19474, Pierce; diluted 1 : 30)
were tested on salivary glands in immunohistochemistry
assays. These antibodies were incubated overnight, washed
with PBS, and incubated with the secondary antibody (goat
anti-rabbit IgG labelled with peroxidase; Abcam ab759). The
colour reaction was induced as previously described and
evaluated in a blinded manner [5].
2.6. Statistical Analyses. Data were processed using a Fisher’s
exact test using the GraphPad Software, QuickCalcs; the two-
tailed 𝑃 value < 0.005 was considered statistically significant.
3. Results
3.1. Lymphocyte Infiltrates. The absence of any inflammatory
infiltrate was classified as a score of 0, which was charac-
teristic of all control biopsies. Five biopsies from Sjögren’s
syndrome patients were scored as class I, and these biopsies
exhibited discrete sialadenitis. Six biopsies were scored as
class II and exhibited a moderate infiltration of mononuclear
cells grouped in a single focus. Five biopsies were scored as
class III and exhibited severe sialadenitis and one infiltrating
focus. Eight biopsies were scored as class IV and displayed
chronic sialadenitis with more than one foci (Table 1).
3.2. Purification and Labelling of High-Affinity Anti-CCP
Antibodies. We purified anti-CCP antibodies, which were
bound to commercial polystyrene plates covered with cit-
rullinated synthetic peptides, from the total protein in each
microwell. We recovered 30 𝜇g/well of specific and high-
affinity anti-CCP antibodies after glycine elution. We used
the traditional coupling method of horseradish peroxidase
bound to anti-CCP antibodies and glutaraldehyde at a molar
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Table 1: Clinical, serologic, and immunohistochemistry data.
Sjögren (𝑛 = 24) Controls (𝑛 = 24)
Clinical data
Sicca 24 (8 = IV, 5 = III, 6 = II, 5 = I) 0 ∗P < 0.0001
Glandular 24 (8 = IV, 5 = III, 6 = II, 5 = I) 0 ∗P < 0.0001
Extraglandular 10 (8 = IV, 2 = III) 0 ∗P < 0.0006
Serology
Anti-CCP 2 (2 = IV) 0 ∗P < 0.4890
+RF 10 (8 = IV, 2 = III) 0 ∗P < 0.0006
+ANA 16 (8 = IV, 5 = III, 3 = II) 0 ∗P < 0.0001
+Anti-La 12 (7 = IV, 4 = III, 1 = II) 0 ∗P < 0.0025
+Anti-Ro 14 (8 = IV, 4 = III, 1 = II, 1 = I) 0 ∗P < 0.0001
Biopsies
Acini Ducts Infiltrates Acini Ducts Infiltrates
PAD 2 17£(8 = IV, 6 = III, 2 = II, 1 = I)
17
£(8 = IV, 6 = III, 2 = II, 1 = I)
12
£(8 = IV, 4 = III) 0 2 0
∗P < 0.0001
CCP 17£(8 = IV, 5 = III, 3 = II, 1 = I)
17
£(8 = IV, 5 = III, 3 = II, 1 = I)
17
£(8 = IV, 5 = III, 3 = II, 1 = I) 0 0 0
∗P < 0.0001
Citrulline 19£(8 = IV, 5 = III, 5 = II, 1 = I)
19
£(8 = IV, 5 = III, 5 = II, 1 = I)
17
£(8 = IV, 5 = III, 3 = II, 1 = I) 0 2 0
∗P < 0.0001
∗Sjögren versus controls.
£Sjögren class IV versus class I = P < 0.003.
Histology class inside the parentheses.
ratio of enzyme: antibody of 10 : 1, which worked well. The
conjugated antibody was further fractionated using gel filtra-
tion chromatography, which produced three fractions. The
first fraction pool contained the HRP-anti-CCP conjugates
(fractions 9–11 or pool 1), and this fraction was very reactive
to CCP by ELISA, with an optical density that was threefold
higher than the original serum titre. The anti-CCP activity
was weaker in the second pool (fractions 12–14 or pool
2). Pool 3 (fractions 18–20) contained the nonconjugated
peroxidase fraction, which was negative for anti-CCP by
ELISA (Figure 1).
3.3. Anti-CCP Antibodies. Two of the samples from primary
Sjögren’s syndrome patients were positive for anti-CCP anti-
bodies in the serum, whereas healthy controls were negative
for anti-CCP antibodies.
3.4. Normal Salivary Glands Express PAD2. Thepeptidylargi-
nine deiminases belong to a family of enzymes that post-
translationally modify proteins at positively charged arginine
residues to neutral citrulline residues via a citrullination
process. These enzymes play a role in various physiological
processes, and they are widely distributed in tissues. There-
fore, we investigated the distribution of these enzymes in
normal salivary glands and observed the discrete presence of
PAD2 in the ductal epithelia of selected minor salivary gland
of some biopsies. However, expression of this enzyme was
absent in the acini.
3.5. Protein Posttranslational Modification Occurs in the Sali-
vary Glands of Sjögren’s Syndrome Patients. We next exam-
ined the presence of posttranslationally citrullinated proteins
in the salivary glands of primary Sjögren’s syndrome patients
using our high-affinity-purified anti-CCP antibodies. We
detected the presence of posttranslationally modified pro-
teins in the salivary ducts, acini, and inflammatory infiltrate
foci of 70% of the Sjögren’s syndrome patient biopsies,
although evidence for this citrullination process was absent
in normal control samples, 𝑃 value <0.0001 (Figures 2 and 3
and Table 1).
3.6. Protein Citrullination Is PAD2 Dependent. The distri-
bution of PAD2 was then compared to the distribution of
citrullinated peptides (according to anti-CCP labelling) to
determine the association between this enzyme and in situ
citrullination. We observed total agreement between the
presence of both factors, which suggested that this expression
was consistent with the extensive areas of citrullination in the
ducts, acini, and inflammatory infiltration foci. These results
strongly support the in situ posttranslational modification of
proteins (Figure 4).
4. Discussion
Theantigenic triggering by posttranslationalmodifications of
normal proteins is an important component of autoimmune
diseases.This process transforms certain protein epitopes that
may trigger an autoimmune response in genetically suscepti-
ble individuals. The present study investigated whether the
salivary glands in Sjögren’s syndrome patients are potential
sources of posttranslational protein modification. Biopsies
from primary Sjögren’s syndrome patients were used to
detect posttranslationally modified proteins using a tag-
induced anti-CCP antibody and immunohistochemistry.The
potential role of the PAD2 enzyme as the catalyst for these
modifications was also assessed. The primary results of
the present study can be summarised as follows. First, the
PAD2 enzyme was detected in some normal salivary glands,
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Figure 3: (a) Comparative immunohistochemistry assay of CCP,
PAD2, and citrulline in controls and Sjögren patients; note that
10% of normal biopsies express the PAD2 enzyme, while Sjögren
patients exclusively express CCP mutually distributed with PAD2.
(b) Distribution of CCP/PAD2 in compartments of salivary glands
of Sjögren patients.
but its expression was increased considerably in Sjögren’s
syndrome patients. Second, the presence of citrullinated
proteins in the salivary tissues of Sjögren’s patients strongly
supports the posttranslational modification of proteins in
situ. Third, the mutual expression of CCP and PAD2 suggests
that posttranslational modifications are enzyme dependent.
Finally, the inflammatory infiltrates were associated with
PAD2 overexpression, which was directly related to the
presence of protein modifications.
The PAD2 enzyme isoform is extensively distributed
in a variety of mammalian tissues, including the nervous
system, skeletal muscle, pancreas, sweet glands, salivary
glands, mammary fat pads, bone marrow, and immune cells
such as monocytes and macrophages [18–20]. The salivary
glands broadly express proteins that may be modified by
PAD, including vimentin, enolase, and others [21–23]. Fur-
thermore, the salivary glands constitutively express PAD2,
and this enzymemay convert arginine residues into citrulline,
which is the cornerstone of the citrullination process. Addi-
tionally, the epithelial and glandular components of salivary
glands express vimentin, enolase, and other proteins that are
potential substrates for PAD2, and some of these proteins
have been recognised as autoantigens in autoimmune dis-
eases, including rheumatoid arthritis. Therefore, we assumed
that all of the necessary elements for posttranslational mod-
ification existed, and these molecules were observed to be
present in the salivary glands of patients with Sjögren’s
syndrome. Following this posttranslational process, modified
proteins have been shown to trigger autoimmune responses.
The first evidence for antibody generation in response to
modified cellular components was reported as the presence
of autoantibodies against filaggrin, which is detected in
normal epithelial cells of the oral mucosa. Therefore, this
autoantibody was termed as an “antiperinuclear factor” and
was shown to be present in rheumatoid arthritis patients.
Similarly, anti-CCP antibodies serve as an early marker
of rheumatoid arthritis, and the importance of anti-CCP
antibodies in disease pathogenesis has been increasingly
demonstrated [24–28]. Furthermore, posttranslational pro-
tein modifications may trigger other autoimmune diseases,
such as optic neuritis, coeliac disease, and multiple sclerosis
[29–31].
The biggest challenge in the current study was the poor
availability of anti-CCP reagents from a commercial source.
Therefore, we obtained autoantibodies from rheumatoid
arthritis patients to perform our studies. We were inspired by
the study of Vossenaar et al. [32], as these authors obtained
affinity-purified antibodies from the serum of rheumatoid
arthritis patients using an immunoadsorption techniquewith
recombinant peptides that were produced by phage display
technology. We used a very simple technology that exploited
the ability of immobilised synthetic peptides on polystyrene
commercial plates to bind high-affinity anti-CCP antibodies,
which were eluted from plates with a glycine buffer that
lowers the pH. This method recovered a useful amount
of high-affinity anti-CCP antibodies, which demonstrated
a threefold increased reactivity to citrullinated synthetic
peptides in commercial ELISA plates. These high-affinity
anti-CCP antibodies were conjugated to peroxidase, which
served as an excellent tag for CCP, as demonstrated in the
immunohistochemistry assays; efficiency of our antibodies
is comparable to that previously reported by other authors
[32]. Furthermore, potential false positives for the presence of
rheumatoid factor were prevented by the preincubation with
normal IgG, which neutralised the rheumatoid factor activity.
Our results are important for understanding Sjögren’s
syndrome pathophysiology because these modifications con-
stitute an additional mechanism for the triggering of autoim-
munity. These modifications may also be applicable to other
autoimmune diseases because posttranslational modification
may represent a common mechanism for the genesis of
autoantigens. For example, the study by Routsias et al.
demonstrated that the posttranslational modification of the
auto-antigen La increased its antigenicity [33, 34]. These
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Figure 4: Immunohistochemistry of minor salivary glands from Sjögren patients; the superior panel shows an overview of immunoreagent
distribution at 10x magnification; the inferior panel showed a close up at 40x magnification. (A) and (E). Incubated with PBS. (B) and
(F). Treated with anti-CCP. (C) and (G). Anti-PAD2. (D) and (H). Anticitrulline. Note the correlation between CCP, PAD2, and citrulline
expression in a duct.
results support a new perspective for exploring the origins
of autoimmunity based on antigenic triggering in genetically
susceptible individuals.
However, many questions remain unresolved. For exam-
ple, do the constitutively expressed PAD enzymes in normal
glandular epithelia (PAD2) play a role in the initial triggering
of autoimmunity in Sjögren’s syndrome? Additionally, do
previous triggers induce inflammatory foci formation and
PAD2 overexpression inmononuclear cells andmacrophages
leading to the posttranslationalmodification of salivary gland
proteins? Both of these possibilities may coexist and create
a feedback loop, although the theoretical aspects of this
hypothesis require clarification using other experimental
approaches.
5. Conclusions
In conclusion, Sjögren’s syndrome patients possess the cat-
alytic machinery to posttranslationally modify proteins,
which may result in auto-antigen triggering.
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